Arbutus Biopharma Corporation
ABUS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $606,941 | $414,901 | $351,689 | $413,283 |
| - Cash | $36,330 | $26,285 | $30,776 | $109,282 |
| + Debt | $1,289 | $8,721 | $2,187 | $2,614 |
| Enterprise Value | $571,900 | $397,337 | $323,100 | $306,615 |
| Revenue | $6,171 | $18,141 | $39,019 | $10,988 |
| % Growth | -66% | -53.5% | 255.1% | – |
| Gross Profit | $6,171 | $18,141 | $39,019 | $10,988 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$68,403 | -$70,986 | -$61,859 | -$71,637 |
| % Margin | -1,108.5% | -391.3% | -158.5% | -652% |
| Net Income | -$69,920 | -$72,849 | -$69,456 | -$76,247 |
| % Margin | -1,133% | -401.6% | -178% | -693.9% |
| EPS Diluted | -0.38 | -0.44 | -0.46 | -0.73 |
| % Growth | 13.6% | 4.3% | 37% | – |
| Operating Cash Flow | -$64,850 | -$85,936 | -$35,356 | -$67,532 |
| Capital Expenditures | -$182 | -$1,008 | -$512 | -$809 |
| Free Cash Flow | -$65,032 | -$86,944 | -$35,868 | -$68,341 |